Two stages exist. First an internal appeal, reviewed by the plan itself. Then an independent external review by an organization outside the plan, whose ruling the plan must implement. Both run on deadlines. For tirzepatide there is also a threshold question worth settling before either stage begins, and it concerns which approved use was reviewed.
Reviewed by Dr. Eric C. Nager, MD, Regenerative Medicine
Start by asking what the reviewer was actually reviewing
The product carries two approved indications: reduction and long-term maintenance of body weight in adults with obesity or overweight with a weight-related condition, and treatment of moderate to severe obstructive sleep apnea in adults with obesity. The second rests on a randomized trial in adults with OSA and obesity and was the first approval of a drug for that condition.
Refusal letters frequently quote a weight-management rule. If the patient’s case was submitted under that indication, the letter is on point. If the treating question was actually sleep apnea, the plan may have applied a rule written for a different use, and that mismatch is a documented, checkable argument rather than a plea. Pointing to the exact criteria set that should have governed is stronger than any general appeal to clinical merit.
Work out whose decision is being contested
Anthem holds a Blue Cross Blue Shield license, runs locally in the states it serves, and sits under the Elevance Health corporate umbrella. Where the employer self-funds, the employer’s money pays the claim and the licensee administers the design the employer bought. That distinction changes which regulator stands behind the process and sometimes which body handles the second stage, so the determination letter should be read for the name of the entity that decided, not just the logo at the top.
Stage one: internal appeal
An internal appeal asks the plan to reconsider, normally through a reviewer who was not part of the original decision. Members generally have up to six months from the notice to file. Three things belong in the submission and little else: the exact criterion or exclusion being contested, dated clinical evidence answering it, and a short cover statement that maps one to the other.
What loses at this stage is anything general. Statements about how well the drug works, what a neighbor received, or what seems fair do not engage the reviewer’s task, which is to compare one file against one written rule. What wins is documentary: a letter of medical necessity quoting the plan’s own wording, chart notes bearing dates, diagnostic reports, and pharmacy history evidencing what was already tried.
Stage two: review outside the plan
When the internal stage ends in another refusal, the member can ask for review by an independent organization not employed by the plan, and the plan is bound by the result. Requests are generally filed within four months of the final internal determination. Depending on how the plan is funded and regulated, the process runs either through the state insurance regulator or through a federally administered route.
The discipline stays the same. Send the determination letters, the criteria document, the clinical records and the mapped summary. External reviewers apply the plan’s own terms, so a tightly matched file beats a thick one every time.
| Stage | Who decides | Typical filing window | What carries it |
|---|---|---|---|
| Internal appeal | The plan or its benefit manager | Up to six months from the notice | Criterion, dated evidence, mapped summary |
| Expedited internal appeal | Same, urgent track | Immediately, on clinical urgency | Clinician statement of risk from delay |
| External review | An independent review organization | Within four months of the final refusal | The complete file, unchanged and organized |
| Expedited external review | Same, urgent track | Can run alongside an urgent internal appeal | The same file, marked urgent |
The indication argument, written out
Where the letter cites an exclusion for drugs used in weight management and the clinical question was obstructive sleep apnea, the appeal should say so in the first paragraph and attach the diagnosis. This is not a workaround. It is a request that the correct rule set be applied to the correct clinical claim. It also has a limit: some plan documents write the exclusion around the molecule itself, in which case both uses are excluded and the argument does not exist. Reading the exclusion’s exact words is what separates those two situations, and it takes minutes.
When the exclusion really does cover everything
An appeal cannot install a benefit the sponsor never bought, and reviewers at both stages will uphold a plan that did exactly what its document said. At that point the work becomes pricing. Eli Lilly and Novo Nordisk operate self-pay pharmacies for their approved products at published figures, and cash practices including Ro, LifeMD, Hims and Hers and FormBlends post monthly program pricing that can be set beside them. Programs built on compounded preparations carry a fact worth stating plainly: compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality.
Public programs run their own ladders
Medicare drug coverage has a separate sequence beginning with a coverage determination and moving through redetermination and further levels, each with its own forms and clocks. Medicaid programs are administered state by state with their own fair hearing processes. Instructions written for employer coverage should not be followed line by line by someone on either.
Someone on commercial coverage whose exclusion is final faces a simpler but less guided choice, since no program ladder applies and the market sets the terms. Here the useful exercise is lining up how each provider structures a month: LillyDirect sells the brand outright, Henry Meds and Ro bundle the visit differently, and HealthRX lists Zepbound beside the rest of its GLP-1 menu. The figure that matters is the ongoing one, not the introductory rate that resets after the first fill.
Questions people ask
Does the appeal have to come from the patient?
The member files it, but an authorized representative can act on their behalf, and prescribing offices frequently do. The office holds the records the reviewer wants and knows how the criteria are worded, so a submission it prepares tends to land better than a letter written from memory at home.
Is the external reviewer genuinely independent?
Yes, and that is the point of the stage. The organization is not employed by the plan and the plan must implement the outcome, which is why the second stage is worth taking even after a discouraging first result. Different people apply the standard to the same file.
Can treatment continue during the appeal?
Only if the member pays for it or an alternative is covered. Pending appeals do not release medication. Because maintenance trials show the effect is tied to continuing therapy, an extended gap is a clinical consideration in itself and worth raising with the prescriber early rather than at the end.
What if the diagnosis changed after the first refusal?
A new diagnosis usually means a new request rather than an appeal, since an appeal contests the decision made on the record that existed. Filing fresh under the correct indication restarts the review with the right criteria and often resolves faster than arguing about the old file.
